Your browser is no longer supported. Please, upgrade your browser.
NEW! Auto Refresh is now available in Screener. Let us know what you think. ×
SNY Sanofi daily Stock Chart
Index- P/E22.61 EPS (ttm)1.96 Insider Own- Shs Outstand2.63B Perf Week0.36%
Market Cap116.73B Forward P/E14.53 EPS next Y3.05 Insider Trans- Shs Float2.35B Perf Month-13.94%
Income5.17B PEG3.43 EPS next Q0.73 Inst Own10.10% Short Float0.06% Perf Quarter-10.09%
Sales38.73B P/S3.01 EPS this Y18.80% Inst Trans-3.02% Short Ratio0.93 Perf Half Y-10.10%
Book/sh23.25 P/B1.91 EPS next Y-2.24% ROA5.10% Target Price55.02 Perf Year-4.79%
Cash/sh1.91 P/C23.16 EPS next 5Y6.60% ROE8.80% 52W Range42.16 - 54.98 Perf YTD0.39%
Dividend1.61 P/FCF- EPS past 5Y-3.90% ROI7.00% 52W High-19.41% Beta1.04
Dividend %3.63% Quick Ratio1.40 Sales past 5Y1.80% Gross Margin68.00% 52W Low5.09% ATR0.90
Employees113496 Current Ratio1.40 Sales Q/Q16.10% Oper. Margin19.00% RSI (14)39.68 Volatility0.98% 1.26%
OptionableYes Debt/Eq0.26 EPS Q/Q65.60% Profit Margin13.40% Rel Volume0.47 Prev Close44.25
ShortableYes LT Debt/Eq0.19 EarningsOct 29 BMO Payout42.20% Avg Volume1.50M Price44.31
Recom2.30 SMA20-3.78% SMA50-7.40% SMA200-10.40% Volume707,968 Change0.14%
Nov-09-15Downgrade Bernstein Outperform → Mkt Perform
Oct-15-15Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-22-15Upgrade Citigroup Sell → Neutral
Apr-15-15Initiated Societe Generale Buy
Aug-03-12Downgrade Standpoint Research Buy → Hold
Jan-11-11Downgrade Jefferies Buy → Hold
Nov-16-09Initiated Deutsche Securities Buy
Oct-14-09Upgrade UBS Sell → Neutral
Aug-28-09Upgrade JP Morgan Neutral → Overweight
Jun-29-09Downgrade JP Morgan Overweight → Neutral
May-28-09Upgrade Citigroup Hold → Buy
Apr-30-09Upgrade JP Morgan Neutral → Overweight
Mar-23-09Upgrade Jefferies & Co Underperform → Hold
Mar-17-09Initiated Credit Suisse Outperform
Feb-19-09Upgrade JP Morgan Underweight → Neutral
Jan-26-09Initiated Jefferies & Co Underperform
Nov-07-08Downgrade UBS Neutral → Sell
Sep-23-08Downgrade Credit Suisse Neutral → Underperform
Oct-24-07Initiated Bernstein Mkt Perform
Sep-06-07Initiated UBS Neutral
Nov-27-15 01:51PM  Exclusive: Lazard works with Sanofi on $12.7 billion animal health unit deal - sources
09:01AM  Volkswagen Rocked the Show for the Third Consecutive Day
09:00AM  Moving Average Analysis of the Top Performers of FEZ and EWJ
08:02AM  Bristol-Myers Looks Beyond Cancer To Build Portfolio at Investor's Business Daily
Nov-25-15 01:14PM  Here is What Hedge Funds Think About Sanofi SA (ADR) (SNY) at Insider Monkey
Nov-24-15 05:21PM  Reading Auto Manufacturings Outperformance on November 23
03:30PM  AstraZeneca to Divest Entocort U.S. Rights to Perrigo
01:00AM  Regeneron and Sanofi Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent® Injection Fully Enrolled PR Newswire
Nov-23-15 04:40PM  AstraZeneca, Sanofi to Swap 210,000 Chemical Compounds
04:06PM  CVS' Amgen Pick 'Raises The Bar' For Regeneron, Sanofi at Investor's Business Daily
03:44PM  Why Are Analysts Buying Myokardia?
11:33AM  Uh Oh, CVS Prefers Amgen's Cholesterol Drug to Regeneron's at
08:00AM  CVS Makes Exclusive Deal to Cover Amgens Cholesterol Drug at Bloomberg
Nov-22-15 11:02AM  Sanofi Sets Its Sights on 2020 -- Here's What Investors Need to Know at Motley Fool
Nov-21-15 08:00AM  5 Things Amgen, Inc. Wants You to Know at Motley Fool
Nov-20-15 03:30PM  Is This One Giant Lurch for MannKind?
02:38PM  Sanofi whistleblower suit kicks into a higher gear at CNBC
02:34PM  Big Pharma Learns to Share at Bloomberg
10:36AM  MannKind Elder Abuse Is Replacing Inept CEO With Founder at TheStreet
10:35AM  Exclusive: JLL makes big life sciences play with new hire at
09:10AM  Sanofi-AstraZeneca chemicals swap takes open route to R&D at Financial Times
09:00AM  Big Pharma firms swap chemical compound libraries at
08:35AM  Perceptions of Counterfeit Medicines: Only 12% of Americans Feel They Have Enough Information PR Newswire
03:03AM  Sanofi, AstraZeneca swap compounds in new twist on open drug R&D
12:23AM  AstraZeneca, Sanofi Agree to Share Proprietary Compounds at The Wall Street Journal
Nov-19-15 07:28PM  Sanofi, AstraZeneca in major drug-sharing deal AFP
07:03PM  AstraZeneca, Sanofi Agree to Share Proprietary Compounds at The Wall Street Journal
07:03PM  AstraZeneca, Sanofi Agree to Share Proprietary Compounds
04:22PM  MannKind's Desperation Move Comes Up Short -- Now What? at Motley Fool
11:55AM  ANTB: Working Towards IND Filing for AB101 and Raising Capital
10:36AM  Total And Sanofi: Two French Stocks Worth Buying Now at Forbes
Nov-18-15 04:09PM  How Did Total Outperform Sanofi?
10:59AM  Weekly 3-Year Low Highlights: Sanofi, Exelon, Cummins, W.W. Grainger
08:36AM  Sanofi and Regeneron Hit Another Bullseye at Motley Fool
Nov-16-15 05:00PM  Korean Billionaire's Gains Pile Up as Pharma Stock Surges 900% at Bloomberg
01:00PM  Why MannKind's Listing in Israel Might Not Matter at Motley Fool
12:01PM  Buffett's not selling overseas he's buying at CNBC
Nov-14-15 07:21AM  These 2 Companies Could Revolutionize Heart Disease Prevention at Motley Fool
03:01AM  Very Little To Celebrate On World Diabetes Day at Forbes
Nov-13-15 10:42AM  It's Time for MannKind Investors to Come to Grips With Reality at Motley Fool
07:27AM  Body's Microorganisms Could Keep Humans More Healthy at Forbes
Nov-12-15 12:31PM  Why MannKind Corporation Is Soaring Today at Motley Fool
11:27AM  Regeneron Recovers From Clinton Biotech Beat Down at Investor's Business Daily
10:32AM  76% of FEZs Holdings Were Trading above 100-Day Moving Averages
10:30AM  Regeneron In Buy Zone As Arthritis Drug Shows Promise
05:04AM  Are Predators Circling GlaxoSmithKline plc?
Nov-11-15 01:13PM  Here's Why MannKind Corporation's Stock Is Crashing Today at Motley Fool
10:58AM  Merck & Co. Is Growing despite Its Revenue Falling in 3Q15
Nov-10-15 06:01PM  Sanofi and Regeneron Announce New Praluent® (alirocumab) Injection Analyses Presented at AHA Scientific Sessions 2015 PR Newswire
06:00PM  Regeneron and Sanofi Announce New Praluent® (alirocumab) Injection Analyses Presented at AHA Scientific Sessions 2015 PR Newswire
04:25PM  What's in Store for Immune (IMDZ) this Earnings Season?
02:15PM  Merrimack (MACK) Reports Narrower-than-Expected Q3 Loss
11:48AM  Why MannKind Corporation Shares Are Down Big Today at Motley Fool
11:03AM  MannKind: Buying TimeBut It's Still All About Afrezza at
10:35AM  Frances Industrial Production Grew Modestly in September
06:58AM  MannKind Migrates to Israel to Stave Off Bankruptcy at TheStreet
05:36AM  [$$] Novo Nordisk: Avoiding the Diabetes Crowd at The Wall Street Journal
Nov-09-15 05:48PM  Sanofi delayed drug to avoid $708 mln in payments, lawsuit claims Reuters
01:40PM  Lexicon Led the Biotechnology Subgroup
01:09PM  Why Relypsa Shares Are Soaring Today at Motley Fool
12:03PM  Sanofi Downgraded After Analyst Day Underwhelms at Investor's Business Daily
11:50AM  Massachusetts owns the orphan drug market. Heres the proof. at
11:25AM  Longtime leader of Aveo Oncology steps down from chairman role at
08:48AM  Ahead of the Bell: Sanofi falls after detailing future
Nov-08-15 10:29AM  Sanofi chief positive on new drugs as he warns on profits at Financial Times
07:08AM  Sanofi and Regeneron Present Results from Pivotal Phase 3 Study of Sarilumab at American College of Rheumatology Annual Meeting PR Newswire
07:00AM  Regeneron and Sanofi Present Results from Pivotal Phase 3 Study of Sarilumab at American College of Rheumatology Annual Meeting PR Newswire
Nov-07-15 10:40AM  Warp Drive Bio emerges from stealth with drugs for 'undruggable' cancers at
Nov-06-15 02:35PM  Lexicon Pharmaceuticals Explodes Higher -- Here's What's Fueling the Surge at Motley Fool -7.58%
02:07PM  Voyager plans IPO liftoff next week amid uncertain market at
12:40PM  New Sanofi boss seen well-placed to lead $13 bln asset selloff Reuters
11:00AM  Sanofi/GSK: across the channel at Financial Times
10:03AM  European stocks turn higher as euro slammed to six-month low at MarketWatch
07:01AM  [$$] Sanofi May Sell Generic Drug, Animal Health Businesses at The Wall Street Journal
01:34AM  Sanofi, Lexicon sign diabetes licence and collaboration deal
01:22AM  Sanofi sees strong profit growth from 2018, to cut costs
01:08AM  Sanofi to consider exit from animal health business at Financial Times
01:01AM  Sanofi and Lexicon Pharmaceuticals to Collaborate on Sotagliflozin, an Investigational New Oral Medicine for People with Diabetes PR Newswire
01:00AM  Sanofi Puts Merial Animal Business, Generics Unit on Review at Bloomberg
Nov-05-15 08:51PM  Korea's Hanmi Soars On Sanofi Tie-Up To Develop Diabetes Drugs at
01:23PM  FEZs Holdings: 65% Were above the 100-Day Moving Average
01:23PM  FEZ Fell Due to Flat Services PMI
12:06PM  Is It Game Over for MannKind Corporation? at Motley Fool
08:10AM  Tufts Explains Why Multiple Breakthroughs Like PCSK9 Cholesterol Drugs Burst On The Scene at Forbes
08:00AM  Sanofi and Regeneron to Present Results from Phase 3 Praluent® (alirocumab) Injection Clinical Trials at AHA Scientific Sessions 2015 PR Newswire
06:32AM  Sanofi, Hanmi seal diabetes licence deal for up to $4.2 bln
02:35AM  Sanofi Inks $435 Million Diabetes Deal With South Korea's Hanmi at Bloomberg
Nov-04-15 12:27PM  Regeneron's 3Q EPS Beat Can't Lift the Stock; Shares Down 4.5% at
10:20AM  Is This Drug Going to Be a Big Threat to Biogen and Novartis Next Year? at Motley Fool
07:17AM  [$$] Regeneron Results Soar on Eye-Treatment Sales at The Wall Street Journal
Nov-03-15 01:00PM  Billionaire Ken Fishers Top Healthcare Stock Picks at Insider Monkey
12:54PM  What to Watch When Regeneron Reports at
09:01AM  The Clock Is Ticking for MannKind at Motley Fool
08:02AM  Roche Touts New MS Drug As Legacy Players Hit Snags at Investor's Business Daily
01:05AM  Sanofi and BioNTech Announce Cancer Immunotherapy Collaboration and License Agreement PR Newswire
Nov-02-15 06:06PM  Eli Lillys 3Q15 Earnings: Major Developments
05:40PM  Novo Nordisk A/S Earnings: Benefiting From a Stronger Dollar at Motley Fool
12:15PM  Dyax is another Massachusetts biotech that can trace its success to Genzyme at
12:58AM  Drug Makers Buy Pricey Vouchers to Speed Products to Market at The Wall Street Journal
Nov-01-15 08:31PM  Drug Makers Buy Pricey Vouchers to Speed Products to Market at The Wall Street Journal
Sanofi researches, develops, and markets various therapeutic solutions. Its products comprise diabetes solutions, including Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; and Afrezza, an inhaled insulin to improve glycemic control, as well as Toujeo, an insulin glargine. The company also offers Cerezyme to treat gaucher disease; Myozyme/Lumizyme for the pompe disease treatment; Fabrazyme for fabry disease treatment; and Aldurazyme to treat mucopolysaccharidosis type I, as well as provides Aubagio and Lemtrada for multiple sclerosis. In addition, it provides Jevtana for prostate cancer; Taxotere for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers; Thymoglobulin to treat acute rejection in organ transplantation, aplastic anemia, and graft-versus-host diseases; Eloxatin for colorectal cancer; Mozobil for treating hematologic malignancies; and Zaltrap for oxaliplatin resistant metastatic colorectal cancer. Further, the company offers other prescription drugs, such as Plavix for atherothrombosis and acute coronary syndrome; Lovenox for the treatment and prevention of deep vein thrombosis and acute coronary syndromes; Aprovel/CoAprovel for hypertension; Renagel/Renvela to treat chronic kidney disease; Depakine for epilepsy; Synvisc/Synvisc-One for the treatment of pain associated with osteoarthritis of the knee; Stilnox/Ambien/Myslee to treat sleep disorders; Multaq for atrial fibrillation; Allegra for the treatment of allergic rhinitis and urticarial; Actonel for osteoporosis and paget's disease; and Auvi-Q/Allerject for the treatment of severe allergic reactions. Additionally, it offers consumer health care products and generic medicines; and vaccine and animal health products. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sanofi10% OwnerNov 03Buy10.00900,0009,000,0003,218,899Nov 05 02:37 PM
Sanofi10% OwnerOct 06Buy472.3311,0405,214,51923,108,570Oct 08 05:50 PM
Sanofi10% OwnerOct 06Buy459.7180,53837,024,19723,097,530Oct 08 05:45 PM
Sanofi10% OwnerJul 27Buy537.4810,6395,718,27222,869,783Jul 29 05:46 PM
Sanofi10% OwnerDec 24Buy398.7930,00211,964,50122,859,144Dec 29 05:40 PM
Sanofi10% OwnerDec 23Buy392.23171,45767,251,14222,829,142Dec 29 05:40 PM